Search

Displaying results 2111 - 2120 of 5924 in total
  1. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  2. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression

  3. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsSynonyms: d-Propoxyphene
  4. Drug

    Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

    go.drugbank.com/drugs/DB15729
    Investigational

    Adipose mesenchymal stem cells (AMSCs) are MSCs derived from adipose tissue, which is more accessible and less painful than stem cells extracted from most other sources. Autologous stem cells are those derived from a patient’s own cells ...

  5. Drug

    Nesvategrast

    go.drugbank.com/drugs/DB19337
    Investigational

    Nesvategrast is under investigation in clinical trial NCT05409235 (Nesvategrast (OTT166) in Diabetic Retinopathy (DR)).

  6. Drug

    Palbociclib

    go.drugbank.com/drugs/DB09073
    ApprovedInvestigational

    It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
  7. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.

  8. Drug

    Lesopitron

    go.drugbank.com/drugs/DB04970
    Experimental

    Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.

  9. Drug

    Chlormadinone

    go.drugbank.com/drugs/DB13528
    Investigational

    Mixtures: ADELLA MINI TABLETA CON RECUBRIMIENTO DE GELATINA, ADELLA MINI TABLETA CON RECUBRIMIENTO DE GELATINACategories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  10. Drug

    Naltalimide

    go.drugbank.com/drugs/DB21082
    Experimental

    Naltalimide has a monoisotopic molecular weight of 472.2 Da.